In 2005, the opioid antagonist naloxone was added to UK's exempt list of prescription-only medicines that could be administered intramuscularly by anyone in an emergency to safe life. In January 2011, Scotland became the first country to introduce a centrally-funded, evaluated National Naloxone Programme (NNP), designed to have 80% power within 3-years to detect a 30% reduction (from 10% to 7%) in its primary outcome: the proportion of opioid-related deaths within 4-weeks aof prison-release 2 . By 2014+15 (calendar years), the primary outcome had reduced to 4% 5 , a 60% reduction compared to 2006-10, see Table 1 .
Every two years, Scotland's Needle Exchange Surveillance Initiative (NESI), which is geographically representative of Scotland's problem drug users, interviews over 2000 people who have recently injected drugs (80% of them within the past 6 months). Ethical approval for NESI was obtained from the NHS West of Scotland Research Ethics Committee. From 2011, NESI asked interviewees about the prescription of take-home naloxone in the past-year, and whether their most recent prescription was from prison 6 . The percentage of NESI respondents prescribed take-home naloxone in the past year increased from 8% in 2011/12 (financial year) through 32% in 2013/14 to 51% in 2015/16, mirroring the increased effectiveness of Scotland's NNP in 2014+2015 (p = 0.013), see Table 1 .
There was, however, a significant decrease in the proportion of take-home nalxoone supplied to NESI respondents by Scottish prisons between 2013/14 and 2015/16 (p = 0.0018), perhaps because regional targets were set (and met) for community-based provision of take-home naloxone to 15% of the regions' problem drug users by the end of 2013/14 (rising to 30% by the end of 2015/16) and before prison-based advisory targets were introduced in 2014/15 2 . We found important heterogeneity of provision of take-home naloxone by gender, age-group, homelessness and recency of injecting with greater provision for people younger than 35 years, the homeless and those who had injected drugs in the past 6 months, see Table 2 ; however, the proportion whose naloxone was most recently received from prison was 13% irrespective of recency of injecting.
When past-year incarceration-rate and average duration of incarceration are taken into account 6 , Table 2 shows that Scottish prisons provided take-home naloxone to 67% (95% CI: 53 to 81) of NESI's female past-year prisoner-releases but to only 39% of their male counterparts (34 to 44); and to 48% (40 to 55) of past-year NESI prisoner-releases aged less than 35 years but to only 37% (31 to 43) of their older counterparts. Community-provision in the past-year was higher for females than males, for those aged less than 35 years than for those aged 35 years or older, and higher for NESI interviewees who had been homeless in the past 6-months than for those who had not. However, community provision was noticeably low at 28% (24 to 32) for those with a history of injection drug use who had not injected in the past 6-months.
As a safeguard against increasing numbers of age-related opioid deaths, naloxone provision should be offered to older clients 3 7 , including those who have not injected in the past 6-months.
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Number 
1: Primary effectiveness of Scotland's NNP in reducing opioid-related deaths with a 4-week antecedent of prison release and increasing past-year prescriptions of take-home naloxone to people who inject drugs
Periods given span 5 calendar-years before and after start of Scotland's continuing National Naloxone Programme (NNP). Information on past-year prescriptions obtained from NESI surveys done approximately 1 year after analysed period. NESI=Needle Exchange Surveillance Initiative. *Data are n (%; 95% CI). 
